Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Yabao Pharmaceutical
Yabao Pharmaceutical
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Yabao Pharmaceuticals and Salus Pharma announce strategic partnership for generic drugs
Yabao Pharmaceuticals is a leading Chinese pharmaceutical company with fully integrated development, manufacturing and commercialisation capabilities
Research & Development
Yabao and Sciecure Pharma to develop, manufacture and commercialise generics for US and China
No financial terms are released
Research & Development
Yabao Pharmaceuticals enters second collaboration with Eli Lilly
To develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule which has completed pre-clinical development
Research & Development
Yabao Pharmaceuticals and University of South Australia announce new drug discovery laboratory
New collaboration will focus on the development of new treatments for cancer
Subscribe now